Cartesian Therapeutics, Inc.RNACNASDAQ
Loading
Year-over-year research & development expense growth
3Y CAGR
-24.1%/yr
Quarterly compound
5Y CAGR
-4.5%/yr
Recent deceleration
Percentile
P64
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 6.43% |
| Q3 2025 | -7.18% |
| Q2 2025 | 1.33% |
| Q1 2025 | 29.79% |
| Q4 2024 | -0.82% |
| Q3 2024 | -9.96% |
| Q2 2024 | 30.02% |
| Q1 2024 | -56.59% |
| Q4 2023 | 72.52% |
| Q3 2023 | -26.88% |
| Q2 2023 | -4.52% |
| Q1 2023 | -1.81% |
| Q4 2022 | 14.68% |
| Q3 2022 | -13.78% |
| Q2 2022 | 8.44% |
| Q1 2022 | -12.94% |
| Q4 2021 | -3.02% |
| Q3 2021 | 44.86% |
| Q2 2021 | 11.22% |
| Q1 2021 | -13.83% |
| Q4 2020 | 8.10% |
| Q3 2020 | 30.10% |
| Q2 2020 | -27.13% |
| Q1 2020 | -2.82% |
| Q4 2019 | 86.97% |
| Q3 2019 | -33.21% |
| Q2 2019 | 65.02% |
| Q1 2019 | -28.31% |
| Q4 2018 | -13.71% |
| Q3 2018 | -17.51% |
| Q2 2018 | 29.34% |
| Q1 2018 | -18.23% |
| Q4 2017 | 43.34% |
| Q3 2017 | -13.55% |
| Q2 2017 | -0.45% |
| Q1 2017 | 0.10% |
| Q4 2016 | 83.24% |
| Q3 2016 | 0.35% |
| Q2 2016 | -9.75% |
| Q1 2016 | -7.81% |